Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.

Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.

Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.

Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.

Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.